Guided Therapeutics, Inc.
GTHP
$0.0831
-$0.0059-6.63%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -42.42% | -44.93% | 173.33% | 653.85% | -9.59% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -42.42% | -44.93% | 173.33% | 653.85% | -9.59% |
| Cost of Revenue | -85.60% | -81.82% | -38.20% | -23.46% | 495.24% |
| Gross Profit | 133.90% | 130.77% | 145.76% | 152.94% | -213.46% |
| SG&A Expenses | -56.32% | -60.74% | -24.54% | 2.42% | 30.65% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -47.35% | -52.93% | -18.82% | 6.25% | 37.79% |
| Operating Income | 47.44% | 53.05% | 20.36% | -3.72% | -39.02% |
| Income Before Tax | 56.19% | 59.25% | 35.76% | 19.65% | -64.82% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 56.19% | 59.25% | 35.76% | 19.65% | -64.82% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 56.19% | 59.25% | 35.76% | 19.65% | -64.82% |
| EBIT | 47.44% | 53.05% | 20.36% | -3.72% | -39.02% |
| EBITDA | 47.53% | 53.17% | 20.49% | -3.57% | -38.70% |
| EPS Basic | 58.96% | 63.06% | 50.83% | 53.22% | 33.80% |
| Normalized Basic EPS | 49.52% | 59.88% | 46.24% | 41.09% | 22.35% |
| EPS Diluted | 57.33% | 61.64% | 50.23% | 53.62% | 35.38% |
| Normalized Diluted EPS | 49.52% | 59.88% | 46.24% | 41.09% | 22.35% |
| Average Basic Shares Outstanding | 10.40% | 17.40% | 32.48% | 57.47% | 109.20% |
| Average Diluted Shares Outstanding | 10.40% | 17.40% | 32.48% | 57.47% | 109.20% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
